Abstract
A 20 year-old female, heterozygous for Factor V Leiden mutation (FVLM) is presented. Her personal history was prominent for severe anaemia during her gestation. Aetiology of anaemia was found to be hereditary spherocytosis (HS). Intrauterine foetal death had occurred at 20 weeks of gestational age. Two days after curettage, she developed pulmonary embolism (PE). This is an unusual case of pulmonary embolism and intrauterine foetal death coexisting with FVLM and/or HS. We present the case so that a general practitioner or haematologist can hardly see such cases in daily practice. Hence, a young female with PE should be screened for hypercoagulable states including FVLM or HS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leroyer C, Mercier B, Escoffre M, Ferec C, Mottier D. Factor V Leiden Prevalence in venous Thromboembolism Patients. Chest 1997;111(6):1603–1606.
Vandenbroucke JP, Bertina RM, Holmes ZR, et al. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998;79(3):511–516.
Heilman Lothar, Schneider D, Tempelhoff GF. Antithrombotic therapy in high-risk pregnancy. Hematol Oncol Clin North Am 2000;14(5):1133–1149.
Lawson HW, Atrash HK, Franks AL. Fatal pulmonary embolism during legal induced abortion in the United States from 1972 to 1985. AmJ Obstet Gynecol 1990;162:986–990.
Tanyel FC, Öcal T, Balkanci F, et al. The factor V leiden mutation: A possible contributor to hepatic artery thrombosis encountered after liver transplantation in a child. J Pediatr Surg 2000;35(4):607–609.
Bertina RM, Koeleman BPC, Koster T, et al. Mutation in Blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.
Linker CA. Current Medical Diagnosis and Treatment. In: Tierney LM, Mcpphee SJ, Papadakis MA, eds. Blood. Connecticut: Appleton & Lange, Stamford 1998:479–533.
Desmarais S, de Moerloose Ph, Reber G, Minazio Ph, Perrier A, Bounameaux H. Resistance to activated protein C in anunselected population of patients with pulmonary embolism. Lancet 1996;347:1374–1375.
Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94(9):3062–3066.
Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg 506-Gln mutation in the gene for factor V (factor V leiden). N Eng J Med 1997;336(6):399–403.
Bounameaux H. Factor V Leiden paradox: Risk of deep vein thrombosis but not of pulmonary embolism. Lancet 2000;356(15):182–183.
Martinelli I, Catteneo M, Panzeri D, Mannuci PM. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997;77:440–443.
Ordonez AJ, Carreira JM, Alvarez CR, Rodriguez JM, Alvarez MV, Coto E. Comparison of the risk of pulmonary embolism and deep vein thrombosis in the presence of factor V Leiden or prothrombin G20210A. Thromb Haemost 2000;83(2):352–354.
Turkstra F, Karemaker R, Kuijer PM, Prins MH, Buller HR. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost 1999;81(3):345–348.
Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V leiden mutation in a United Kingdom population. Thromb Haemost 1997;77:1215–1224.
Gül A, Özbek U, Öztürk C, İnanc M, Konice M, Özçelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's Disease. Br J Rheum 1996;35:1178–1180.
Gürgey A, Rustemov R, Parlak H, Balta G. Prevalence of factor V Leiden and methylenetetrahydrofolate reductase C677T mutation in Azarbaijan. Thromb Haemost 1998;80:520–521.
De Stefano V, Mastrangelo S, Paciaroni K, et al. Thrombotic risk during pregnancy and puerperium in women with APC resistance-Affective subcutenous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995;74:793–794.
Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902–905.
Mc Coll MD, Ramsay Jei Tait Rc, Walker ID, et al. Risk Factors for Pregnancy Associated venous Thromboembolism. Thromb Haemost 1997;78:1183–1188.
Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for foetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130(9):736–739.
Eichinger S, Waltermann A, Philipp K, et al. Haemostatic system activation and thrombin potential in pregnancy. Thromb Haemost 1999;82:1232–1236.
Hayag-Barin JE, Smith RE, Tucker FC. Hereditary spherocytosis, and Chronic pulmonary emboli: A case report and review of the literature. Am J Hematol 1998;57:82–84.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karnak, D., Beder, S., Kayacan, O. et al. Postoperative Pulmonary Embolism in a Young Female Accompanying with Factor V Leiden Mutation and Hereditary Sypherocytosis. J Thromb Thrombolysis 17, 213–217 (2004). https://doi.org/10.1023/B:THRO.0000040491.79092.11
Issue Date:
DOI: https://doi.org/10.1023/B:THRO.0000040491.79092.11